Stella G Yarve, NP
Nurse Practitioner · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
- Since medical school
- 12 years
- Graduated 2014
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Stella G Yarve’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$488 in 2024
Medicaid paid $488 for 56 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 42 | $488 |
| Medication list documented in medical record (COA) | 14 | $0 |
| 2024 | 56 | 2 | 15 | $488 |
| 2023 | 14 | 1 | 14 | $207 |
See the largest Medicaid services in earlier years
2023
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 14 | $207 |
Drugs they prescribed that Part D paid
$571,272
Pharmacies billed $571,272 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (24 of 657) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
555 generic and 102 brand-name prescriptions · $571,272 in drug cost · 25 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xarelto | 24 | $18,164 | $757 |
| Exemestane | 28 | $7,351 | $263 |
| Enoxaparin | 12 | $4,677 | $390 |
| Anastrozole | 122 | $2,045 | $17 |
| Tamoxifen Citrate | 33 | $918 | $28 |
See all 14 drugs
| Xarelto | 24 | $18,164 | $757 |
| Exemestane | 28 | $7,351 | $263 |
| Enoxaparin | 12 | $4,677 | $390 |
| Anastrozole | 122 | $2,045 | $17 |
| Tamoxifen Citrate | 33 | $918 | $28 |
| Gabapentin | 55 | $508 | $9 |
| Triamcinolone Acetonide | 13 | $298 | $23 |
| Letrozole | 18 | $234 | $13 |
| Alendronate | 43 | $212 | $5 |
| Oxycodone | 20 | $144 | $7 |
| Loperamide | 11 | $142 | $13 |
| Acyclovir | 11 | $111 | $10 |
| Famotidine | 22 | $85 | $4 |
| Omeprazole | 15 | $30 | $2 |
Year by year
| 2024 | 657 | 180 | 4% (24) | 16% | $571,272 |
| 2023 | 684 | 172 | 3% (23) | None | $1,115,171 |
| 2022 | 632 | 169 | 5% (32) | None | $460,586 |
| 2021 | 460 | 142 | 6% (29) | None | $375,636 |
| 2020 | 625 | 137 | 6% (38) | None | $450,107 |
| 2019 | 526 | 143 | 10% (53) | 10% | $109,591 |
| 2018 | 306 | 105 | 40% (123) | 8% | $28,006 |
| 2017 | 275 | 60 | 53% (145) | 11% | $23,068 |
| 2016 | 314 | 75 | 59% (185) | 15% | $26,380 |
| 2015 | 29 | 13 | 45% (13) | None | $1,287 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Promacta | 12 | $224,847 | $18,737 |
| Xarelto | 22 | $18,563 | $844 |
| Anastrozole | 113 | $5,772 | $51 |
| Exemestane | 18 | $3,635 | $202 |
| Tamoxifen Citrate | 30 | $1,411 | $47 |
| Alendronate | 65 | $1,127 | $17 |
| Gabapentin | 55 | $1,018 | $19 |
| Hydroxyurea | 32 | $805 | $25 |
| Letrozole | 14 | $782 | $56 |
| Acyclovir | 29 | $586 | $20 |
| Omeprazole | 12 | $370 | $31 |
| Famotidine | 25 | $236 | $9 |
| Hydrocodone-Acetaminophen | 13 | $78 | $6 |
| Trazodone | 14 | $57 | $4 |
2022: 14 drugs
| Xarelto | 13 | $9,435 | $726 |
| Anastrozole | 107 | $2,954 | $28 |
| Hydroxyurea | 38 | $991 | $26 |
| Letrozole | 19 | $801 | $42 |
| Gabapentin | 52 | $741 | $14 |
| Tamoxifen Citrate | 27 | $718 | $27 |
| Alendronate | 62 | $667 | $11 |
| Hydrocodone-Acetaminophen | 15 | $273 | $18 |
| Acyclovir | 18 | $269 | $15 |
| Zolpidem | 13 | $116 | $9 |
| Dexamethasone | 16 | $112 | $7 |
| Famotidine | 11 | $102 | $9 |
| Trazodone | 15 | $55 | $4 |
| Omeprazole | 20 | $54 | $3 |
2021: 12 drugs
| Enoxaparin | 12 | $4,568 | $381 |
| Exemestane | 16 | $3,160 | $198 |
| Anastrozole | 65 | $1,767 | $27 |
| Letrozole | 27 | $941 | $35 |
| Tamoxifen Citrate | 16 | $853 | $53 |
| Gabapentin | 31 | $435 | $14 |
| Alendronate | 36 | $302 | $8 |
| Acyclovir | 17 | $261 | $15 |
| Hydrocodone-Acetaminophen | 23 | $254 | $11 |
| Zolpidem | 13 | $104 | $8 |
| Losartan | 12 | $79 | $7 |
| Triamcinolone Acetonide | 11 | $67 | $6 |
2020: 19 drugs
| Promacta | 15 | $310,396 | $20,693 |
| Exemestane | 20 | $8,175 | $409 |
| Enoxaparin | 13 | $6,489 | $499 |
| Anastrozole | 94 | $2,298 | $24 |
| Colchicine | 11 | $1,281 | $116 |
| Letrozole | 60 | $1,279 | $21 |
| Tamoxifen Citrate | 20 | $802 | $40 |
| Hydroxyurea | 16 | $398 | $25 |
| Hydrocodone-Acetaminophen | 19 | $344 | $18 |
| Ondansetron | 13 | $324 | $25 |
| Gabapentin | 31 | $308 | $10 |
| Alendronate | 48 | $261 | $5 |
| Levothyroxine | 15 | $181 | $12 |
| Oxycodone | 12 | $129 | $11 |
| Zolpidem | 13 | $113 | $9 |
| Acyclovir | 13 | $101 | $8 |
| Dexamethasone | 11 | $86 | $8 |
| Losartan | 11 | $32 | $3 |
| Carvedilol | 11 | $29 | $3 |
2019: 8 drugs
| Anastrozole | 64 | $1,438 | $22 |
| Letrozole | 60 | $1,216 | $20 |
| Tamoxifen Citrate | 16 | $687 | $43 |
| Oxycodone | 21 | $524 | $25 |
| Alendronate | 47 | $408 | $9 |
| Hydrocodone-Acetaminophen | 23 | $367 | $16 |
| Gabapentin | 27 | $284 | $11 |
| Acyclovir | 16 | $159 | $10 |
2018: 7 drugs
| Oxycodone | 39 | $1,116 | $29 |
| Fentanyl | 13 | $827 | $64 |
| Hydrocodone-Acetaminophen | 24 | $644 | $27 |
| Morphine Sulfate Er | 11 | $432 | $39 |
| Hydromorphone | 16 | $368 | $23 |
| Gabapentin | 29 | $339 | $12 |
| Letrozole | 11 | $185 | $17 |
2017: 8 drugs
| Oxycontin | 12 | $8,591 | $716 |
| Fentanyl | 23 | $1,703 | $74 |
| Morphine Sulfate Er | 16 | $1,355 | $85 |
| Oxycodone | 23 | $1,021 | $44 |
| Hydrocodone-Acetaminophen | 29 | $810 | $28 |
| Hydromorphone | 19 | $639 | $34 |
| Duloxetine | 12 | $306 | $25 |
| Gabapentin | 24 | $204 | $9 |
2016: 8 drugs
| Oxycontin | 20 | $10,645 | $532 |
| Morphine Sulfate Er | 35 | $4,156 | $119 |
| Oxycodone | 34 | $1,320 | $39 |
| Fentanyl | 13 | $1,207 | $93 |
| Hydromorphone | 28 | $1,145 | $41 |
| Hydrocodone-Acetaminophen | 25 | $976 | $39 |
| Methadone | 16 | $198 | $12 |
| Lorazepam | 14 | $72 | $5 |
Professional record
- NPI
- 1376950915
- Licence
- CA 95000842
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-07-15
- NPI last updated
- 2016-03-22
This is when the NPI record was last certified, not a medical board exam.